The significant expression of TRPV3 in nasal polyps of eosinophilic chronic rhinosinusitis

Takahiro Tokunaga a, b, *, Takahiro Ninomiya a, b, Yukinori Kato a, Yoshimasa Imoto a, Masafumi Sakashita a, Tetsuji Takabayashi a, Emiko Noguchi b, Shigeharu Fujieda a

a Division of Otorhinolaryngology – Head & Neck Surgery, Department of Sensory and Locomotor Medicine, Faculty of Medical Science, University of Fukui, Fukui, Japan
b Department of Medical Genetics, Institute of Basic Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan

Abstract

Background: The number of patients with eosinophilic chronic rhinosinusitis (ECRS) has been increasing in recent years in Japan. In ECRS, nasal polyps recur immediately after endoscopic sinus surgery. The molecular biological mechanism underlying the refractoriness of ECRS is unclear.

Methods: Whole-transcriptome analysis with next-generation sequencing (RNA-seq) was conducted to investigate the molecular biological mechanism of ECRS. Real-time PCR, immunohistochemical staining, and immunofluorescence staining were performed to validate the results of RNA-seq.

Results: RNA-seq analysis revealed that in the nasal polyps of ECRS, the levels of 3 transcripts were elevated significantly and those of 7 transcripts were diminished significantly. Among the genes encoding these transcripts, TRPV3 (transient receptor potential cation channel, subfamily V, member 3) was identified as the only gene that is highly expressed in ECRS nasal polyps but this gene's expression was not previously detected using DNA microarray analysis in peripheral blood eosinophils. TRPV3 is newly identified here as a gene transcribed in ECRS. Our analysis also revealed that TRPV3 was highly expressed in the infiltrating eosinophils and mucosal epithelium of the nasal polyps of ECRS, and further that the more severe the refractoriness was after surgery, the higher the TRPV3 expression was in nasal polyps.

Conclusions: TRPV3 might play a role in the refractoriness of ECRS. Additional studies are required to evaluate the function of TRPV3 in ECRS.

Introduction

Chronic rhinosinusitis (CRS) is a highly common chronic nasal disease, and its symptoms include nasal purulent discharge, nasal congestion, and hyposmia. Several variants of CRS are presented due to diverse underlying cellular and molecular mechanisms, and the phenotypes of CRS are heterogeneous. 1 CRS with nasal polyps (CRSwNP) exhibits more intense eosinophilic infiltration and presence of T-helper type 2 (Th2) cytokines in Western countries than elsewhere; conversely, in East Asia, including in Japan, neutrophil infiltration was previously predominant in CRSwNP. 2 However, in recent years, the number of CRS cases with mucosal eosinophilia has been increasing in Japan with the westernization of eating habits and environments. In eosinophilic cases of CRSwNP, nasal polyps recur immediately after endoscopic sinus surgery.
in bronchial asthma, aspirin intolerance, nonsteroidal anti-inflammatory drug intolerance, peripheral blood eosinophilia, and ethmoid-dominant shadow in CT. According to these factors, our algorithm classified CRS into 4 groups: non-ECRS, mild ECRS, moderate ECRS, and severe ECRS. These groups were significantly correlated with the rate of disease recurrence and refractoriness.

Gene expression is an essential factor underlying cellular phenotypes, and a comprehensive catalog of gene transcripts, their structures, and abundance facilitates the elucidation of how gene expression determines phenotypic manifestations. The use of DNA microarrays has served as the effective method of choice in gene-expression studies because the microarrays can be used to concurrently probe thousands of transcripts. Although this is a high-throughput approach, it is likely to bias the results because of, for example, the dependency on existing gene models and the potential for cross-hybridization with probes featuring similar sequences. RNA sequencing (RNA-seq) performed using next-generation sequencers is a comparatively new method for analyzing gene expression, and it provides digital readouts for mapping and quantifying transcriptomes. In RNA-seq, the following procedure is used: a population of RNA is isolated and transformed into a library of cDNA fragments with adaptors attached, and the cDNA library is then sequenced to obtain short sequences (typically 30–400 nucleotides long) and these short reads are mapped to a reference genome or assembled de novo. Subsequently, the expression levels of genes can be determined by counting the number of reads that are aligned to their exons. RNA-seq studies have revealed unknown aspects of transcriptomes, including sequence information on not only exons, but also transcriptional start sites, 5′-untranslated regions, upstream open reading frames, and alternative splicing events.

Currently, the pathophysiological features of ECRS remain unestablished. Moreover, no reports have been published to date on RNA-seq analysis of ECRS. In this study, we performed RNA-seq analysis of the nasal polyps of CRS in order to reveal the transcripts related to the refractoriness of ECRS. We compared and ed and validated the transcripts that exhibited high expression in ECRS.

Methods

Patients of RNA-seq

Nasal polyps were obtained from 10 CRS patients by means of ESS performed at the University of Fukui Hospital, Japan. ECRS was diagnosed based on the JESREC criterion and algorithm, which divided the 10 CRS patients into ECRS and non-ECRS groups.

Table 1 and Supplementary Table 1 list the details of the patients’ characteristics.

Table 1

<table>
<thead>
<tr>
<th></th>
<th>ECRS</th>
<th>Non-ECRS</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>5</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Male/Female</td>
<td>2/3</td>
<td>4/1</td>
<td>n.s.</td>
</tr>
<tr>
<td>Age</td>
<td>36 [29–52]</td>
<td>58 [57–59]</td>
<td>0.047*</td>
</tr>
<tr>
<td>Number of eosinophils in NP (HPF)</td>
<td>214.0 [155.0–249.0]</td>
<td>50.0 [5.0–6.0]</td>
<td>0.012*</td>
</tr>
<tr>
<td>Peripheral blood eosinophils (%)</td>
<td>13.5 [10.6–13.6]</td>
<td>2.3 [1.8–3.2]</td>
<td>0.008**</td>
</tr>
</tbody>
</table>

Representative values shown as medians with interquartile ranges (in brackets). *p < 0.05, **p < 0.01, Wilcoxon rank-sum test. ECRS, eosinophilic chronic rhinosinusitis; NP, nasal polyps; HPF, high-power field. χ²-test.

Library preparation and next-generation sequencing

We used 300–450 ng of RNA-depleted mRNAs for preparing libraries by using a SOLiD™ Total RNA-Seq Kit (Life Technologies, Grand Island, NY, USA) as per the manufacturer's instructions. The complete library preparation protocol is available at http://tools.invitrogen.com/content/sfs/manuals/cms_078610.pdf. The libraries were subjected to emulsion PCR (SOLiD™ EZ Bead™ Emulsifier kit, Life Technologies) to generate clonal DNA fragments on beads, and this was followed by bead enrichment (SOLiD™ EZ Bead™ Enrichment kit, Life Technologies). Enriched template beads were sequenced on a SOLiD™ 5500xl system (Life Technologies) as single-end, 75-bp reads. Library preparation, fragment-library protocols, emulsion PCR, and all SOLiD-run parameters followed standard Applied Biosystems protocols.

Mapping and processing of sequence data

The obtained sequences were aligned with UCSC human genome 19 (hg19) by using Lifescope™ Genomic Analysis Solutions version 2.3.1 (Life Technologies). Lifescope's default settings were used: 40 alignments per read were allowed, with up to 2 mismatches per alignment.

The resulting aligned reads were analyzed further using Avadis™ NGS v1.4.1 (Strand Scientific Intelligence, San Francisco, CA, USA). Avadis NGS assembled the aligned reads into transcripts, either with or without a reference genome (UCSC transcripts), and reported the expression of those transcripts in “Reads Per Kilobase of exon per Million mapped reads,” or RPMK, which is an expression of the relative abundance of transcripts. The t test was used to determine differential expression of transcripts in non-ECRS and ECRS samples. The results of multiple tests were corrected using the Benjamini–Hochberg false-discovery rate.

Quantitative real-time RT-PCR (qRT-PCR)

RNA was isolated from nasal polyps obtained from 40 CRS patients except for those of RNA-seq. The polyps were obtained by means of ESS performed at the University of Fukui Hospital, Japan.
ECRS was diagnosed based on the JESREC criterion and algorithm. We performed qRT-PCR by using the TaqMan® Universal Master Mix and Gene Expression Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. Primer and probe set for TRPV3 (Hs00376854_m1) was purchased from Applied Biosystems.

**Immunohistochemical staining**

Nasal polyp specimens were collected from 80 CRS patients except for those of RNA-seq. The polyps were obtained by means of ESS performed at the University of Fukui Hospital, Japan. ECRS was diagnosed based on the JESREC criterion and algorithm. The specimens were fixed in neutral buffered formalin (10% (v/v) formalin in water, pH 7.4) and embedded in paraffin wax. Immunohistochemical staining was performed on 4-mm-thick sections by using a TRPV3-specific antibody (Sigma–Aldrich, St. Louis, MO, USA). The number of positive cells of TRPV3 in the mucosal epithelial cells was counted at HPF (×400) in the three densest areas, and the mean number of positive cells was calculated. Histological examinations were performed unaware of the clinical data. Images from immunofluorescence slides were obtained with an Olympus BX53 inverted research microscope and were collected by using cellSens® Standard software (Olympus, Tokyo, Japan).

**Immunofluorescence staining**

Nasal polyp specimens were collected from ECRS patients. Peripheral blood was collected from ECRS patients and normal control subjects. The nasal polyp specimens were fixed in neutral buffered formalin (10% (v/v) formalin in water, pH 7.4) and embedded in paraffin wax. Eosinophils were isolated from peripheral blood mononuclear cells by using MACS® Cell Separation system (Miltenyi Biotech, Bergisch Gladbach, Germany) and were cytospun onto glass slides. To stain TRPV3 and ECP (eosinophil cationic protein), samples were incubated with TRPV3-specific antibody produced in mouse (Sigma–Aldrich) and ECP-specific antibody produced in rabbit (Bioss Antibodies, Woburn, MA, USA) at the dilution mentioned above overnight at 4 °C. After washing with PBS, samples were incubated with Alexa Fluor® 594-conjugated goat anti-mouse IgG (Invitrogen, Carlsbad, CA, USA) and Alexa Fluor® 488-conjugated goat anti-rabbit IgG (Invitrogen) for 1 h at room temperature in the dark. After final washing with PBS, coverslips were mounted onto slides by using SlowFade® Gold Antifade Mountant with DAPI (Thermo Fisher Scientific, Waltham, MA, USA). Images from immunofluorescence slides were obtained with an Olympus BX53 inverted research microscope and were collected by using cellSens® Standard software (Olympus).

**Microarray analysis**

Microarray assays were performed using the same samples as those used for RNA-seq. We performed microarray assays by using the Illumina BeadArray single-color platform (Illumina, San Diego, CA, USA). In the assay, cRNA was synthesized by using an Illumina TotalPrep RNA Amplification Kit (Ambion, Austin, TX, USA) according to the manufacturer’s instructions: 500-ng aliquots of total RNA were reverse-transcribed into first- and second-strand cDNA, and then transcribed to acquire biotin-labeled cRNA. A total of 750 ng of biotin-labeled cRNA was hybridized to each HumanHT-12 v4 Expression BeadChip Kit (Illumina) at 58 °C for 20 h. The hybridized BeadChip was washed and labeled with streptavidin-Cy3 (GE Healthcare, Waukesha, WI, USA) and then scanned with the Illumina BeadStation 500 System (Illumina). We prepared duplicate samples from the same cRNA sample for each BeadChip in order to assess whether the assay performed adequately. The correlation coefficients for replicating RNAs were 0.995—0.998 (r²).

RNA-seq data were compared with microarray data. All data were log2-normalized.

**Statistical analysis**

All data are reported as means ± standard deviation unless otherwise noted. Differences between groups were analyzed by performing one-way ANOVA with Tukey post hoc testing or Student’s t test. Correlations were assessed by using the Pearson correlation. A p value or a corrected p value (“q value”) of <0.05 was considered statistically significant. Besides using the statistical tools embedded in Avadis NGS, we performed additional statistical analyses by using R version 2.13.1 for MacOSX GUI 1.40-devel Leopard build 64-bit (R-project, http://www.r-project.org/) and Prism 5.0b for MacOS (MDF, Tokyo, Japan).

**Ethical issue**

All patients provided informed consent, and the protocol and consent forms governing the procedures for the study were approved by the Research Ethics Committee of the University of Fukui (#20120076).

**Results**

**Alignment results**

In the 110 ± 7.1 million-read dataset per sample, 58 ± 8.1% of the reads aligned to the human genome reference hg19. Although <3% of the human genome is composed of exons, 62 ± 2.8% of our uniquely mapped reads overlap gene code exons. These results confirm that our RNA samples are highly enriched for exonic sequences.

**Expression analysis**

To estimate the expression levels of genes in nasal polyps, we used all of the obtained sequence reads (Fig. 1). A gene’s expression level is given by the sum of the RPKM values of its isoforms. The

![Fig. 1. Flowchart of differential-expression analysis. Differential-expression analysis was performed on the 19,932 transcripts obtained after excluding low-expression transcripts from all samples. Sex-chromosome genes were also excluded from the analysis. Analysis threshold was set as >5-fold. The positive and negative values reflect high and low expression in ECRS, respectively. N, number of transcripts.](image-url)
distribution of RPKM values was skewed, and the median RPKM values of non-ECRS and ECRS were 33.8 and 32.5, respectively. A total of 36,579 transcripts from the nasal polyps mapped to the reference transcriptome hg19 from UCSC, and 19,932 analyzable transcripts were selected after excluding all of the low-expression transcripts from all samples. Differential-expression analysis was performed on these 19,932 transcripts, and 12 transcripts were found to differ in a statistically significant manner by >5 times between ECRS and non-ECRS. The 12 transcripts included 10 known and 2 previously unidentified transcripts. Details of the transcripts are included in Table 2.

We found that 3 transcripts were expressed at elevated levels in the nasal polyps of ECRS, and among these, the transcript for TRPV3 (transient receptor potential cation channel, subfamily V, member 3) was the only transcript whose expression was not detected in peripheral eosinophils by using microarray analysis. TRPV3 expression

Real-time PCR and immunohistochemical staining were performed to validate the RNA-seq results: Real-time PCR analysis, performed in 20 non-ECRS cases and 20 ECRS cases, revealed that TRPV3 was expressed at significantly higher levels in the nasal polyp of ECRS than in that of non-ECRS. Expression levels of TRPV3 mRNA per nanogram of total RNA were 45.2 ± 61.9 copies for non-ECRS and 640.1 ± 819.4 copies for ECRS (Fig. 2A). Moreover, immunohistochemistry were performed in 80 patients: 20 cases of non-ECRS, 20 cases of mild ECRS, 20 cases of moderate ECRS, and 20 cases of severe ECRS. Immunohistochemistry results showed that TRPV3 was highly expressed in the infiltrating cells and mucosal epithelium of the nasal polyps of ECRS (Fig. 2B). To investigate whether the infiltrating TRPV3+ cells are eosinophils or not, immunofluorescence were performed in nasal polyps. Immunofluorescence results showed that ECP was highly expressed in the infiltrating TRPV3+ cells of the nasal polyps of ECRS (Fig. 2C). These results suggest that the infiltrating TRPV3+ cells were eosinophils. Moreover, immunofluorescence staining were performed to investigate whether TRPV3 is expressed in peripheral eosinophils or not. TRPV3 was highly expressed in peripheral eosinophils of both ECRS patients and normal control subjects (Fig. 2D). These results were inconsistent with the result of microarray analysis.

Association between the refractoriness of ECRS and TRPV3 expression

Comparison of the expression in the 4 groups identified using the JESREC algorithm showed that the more severe the refractoriness was, the higher the level of TRPV3 expression was in epithelial cells of nasal polyps. The numbers of positive cells of TRPV3 expression were 16.2 ± 10.9/HPF for non-ECRS, 33.7 ± 20.6/HPF for mild ECRS, 68.4 ± 29.9/HPF for moderate ECRS, and 52.9 ± 25.2/HPF for severe ECRS (Fig. 3A). Correlation between TRPV3+ epithelial cells and infiltrating eosinophils was only a modest, and thus higher level of TRPV3 expression of epithelial cells was independent of an influence of the numbers of infiltrating eosinophils on the refractoriness of ECRS (Fig. 3B).

Discussion

In this study, we used next-generation sequencing to perform whole-transcriptome analysis on the nasal polyps of ECRS. This is the first report of a study of this type. We focused on TRPV3, the gene specifically expressed in the nasal polyps of ECRS. ECRS is often associated with bronchial asthma. TRPA1 and TRPM8, another subtypes of transient receptor potential (TRP) channel family, may play important roles in the development of bronchial asthma. TRPA1 is expressed in lung fibroblasts,11 and it is linked to airway inflammation.14 TRPM8 is expressed in trigeminal afferent nerves innervating the broncho-pulmonary system, which may increase airway resistance with neural activation. Activated TRPM8 may be of relevance to aggravation of bronchial asthma.15 However, there is no report that TRPV3 is expressed in bronchial tissues of asthma. TRPV3 may be a specific molecule in ECRS. TRPV3 has been widely investigated in skin keratinocytes, and Yamamoto-Kasai et al. reported that TRPV3 expressed in these cells contributes to the regulation of dendritic cells in atopic dermatitis.16 However, the function of TRPV3 in the nasal mucous epithelium remains to be clarified.

The TRP channel family represents a group of temperature-sensitive ion channels located on the plasma membrane; these channels contain 6 transmembrane domains andcytosolic N- and C-terminal tails. In recent years, proteins of the TRP channel family, including TRPV1 (capsaicin receptor), have attracted considerable research attention as potential targets for drug development. TRP channels are activated by several chemicals, osmotic stimuli, temperature stimuli, and neuropathic pain, and thus the channels function as transducers that convert environmental information into electronic signals through the flow of cations into the intracellular fluid. Epithelial cells harboring specific activated TRP channels release inflammatory substances such as prostaglandin E217 and other cytokines. Furthermore, TRPV3 regulates intracellular nitric oxide (NO) synthesis through nitrite reduction independently of NO synthase.18 A randomized control trial study of CRS patients demonstrated that in patients treated with capsaicin, nasal polyps were significantly smaller than in control patients.19 These results suggest that the TRP channel family might contribute to inflammation, even if it occurs in the airway.20 TRPV3 is located at chromosome 17p13 and is immediately next to TRPV1, the gene that encodes the capsaicin receptor. The TRPV3 gene contains 18 exons and encodes a Ca2+–permeable nonselective cation channel that is broadly expressed in skin keratinocytes and oral and nasal mucous epithelia. TRPV3 belongs to the group of warm-sensitive TRP channels whose activation-temperature thresholds range from 31 to 39 °C.21 Furthermore, several chemical activators for TRPV3 have been identified, and among these, 2-aminoethoxydiphenyl borate, which was first described as an inhibitor of inositol trisphosphate receptors,22 is the most frequently reported activator.23,24 Synergism between chemical ligands and temperature and between structurally different chemical ligands is generally observed for thermosensitive TRPV channels; this phenomenon has been described in detail and discussed in a recent review.25 Other reported TRPV3 activators include camphor,26,27

### Table 2

Differentially expressed transcripts.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Locus</th>
<th>Gene type</th>
<th>Fold-change</th>
<th>q value</th>
<th>Eosinophil</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIGLEC8</td>
<td>chr 19</td>
<td>Protein-coding</td>
<td>7.76</td>
<td>0.047</td>
<td>P</td>
</tr>
<tr>
<td>TRPV3</td>
<td>chr 17</td>
<td>Protein-coding</td>
<td>5.81</td>
<td>0.045</td>
<td>A</td>
</tr>
<tr>
<td>GPR97</td>
<td>chr 16</td>
<td>Protein-coding</td>
<td>5.56</td>
<td>0.047</td>
<td>P</td>
</tr>
<tr>
<td>LOC285141</td>
<td>chr 2</td>
<td>Protein-coding</td>
<td>-5.41</td>
<td>0.045</td>
<td>N/A</td>
</tr>
<tr>
<td>HABP2</td>
<td>chr 10</td>
<td>Protein-coding</td>
<td>-6.22</td>
<td>0.045</td>
<td>A</td>
</tr>
<tr>
<td>C12orf18</td>
<td>chr 1</td>
<td>Protein-coding</td>
<td>-6.59</td>
<td>0.046</td>
<td>N/A</td>
</tr>
<tr>
<td>LOC100652764</td>
<td>chr 1</td>
<td>mRNAs</td>
<td>-6.79</td>
<td>0.030</td>
<td>N/A</td>
</tr>
<tr>
<td>SCCG3</td>
<td>chr 15</td>
<td>Protein-coding</td>
<td>-7.57</td>
<td>0.030</td>
<td>A</td>
</tr>
<tr>
<td>LRRC78</td>
<td>chr 10</td>
<td>Protein-coding</td>
<td>-9.98</td>
<td>0.046</td>
<td>A</td>
</tr>
<tr>
<td>C1orf129</td>
<td>chr 1</td>
<td>Protein-coding</td>
<td>-11.47</td>
<td>0.030</td>
<td>N/A</td>
</tr>
</tbody>
</table>

P, present; A, absent; N/A, not applicable; ECRS, eosinophilic chronic rhinosinusitis.

Expression profile in peripheral eosinophils determined through microarray analysis by Saito et al.12
carvacrol, eugenol, thymol,\textsuperscript{28} and menthol,\textsuperscript{29} which are commonly recognized as flavoring components or skin intensifiers.\textsuperscript{30,31} The effect of these components on nasal symptom was examined in several studies. Schriever \textit{et al.} showed that subjective nasal patency of patients with olfactory dysfunction increased with oral menthol application.\textsuperscript{32} Whereas these several natural and synthetic materials have been described as TRPV3 activators, the intrinsic activators of TRPV3 remain undefined. However, farnesyl pyrophosphate, an intermediate in the steroid-hormone biosynthesis pathway, has been shown to strongly and specifically activate TRPV3.\textsuperscript{33}

TRPV3 regulates diverse functions in skin keratinocyte, including temperature sensing, skin barrier formation, wound healing, hair growth, and itch and pain perceptions.\textsuperscript{34} Cheng \textit{et al.} showed that keratinocyte TRPV3 forms a signaling complex with transforming growth factor-\(\alpha\) (TGF-\(\alpha\)) and epidermal growth factor receptor (EGFR); EGFR activation leads to enhanced TRPV3 channel activity, which in turn stimulates TGF-\(\alpha\) release.\textsuperscript{35} TGF-\(\alpha\) expression in the submucosal tissue was markedly higher in ECRS patients than in non-ECRS patients. Furthermore TGF-\(\alpha\) synergized with tumor necrosis factor-\(\alpha\) and thereby upregulated mucin 5AC expression in human epithelial cells through the extracellular signal-regulated kinase signaling pathway.\textsuperscript{36} If TRPV3 forms a signaling complex with TGF-\(\alpha\)/EGFR in the nasal polyps of ECRS, TRPV3 might play a role in mucous hypersecretion, mucous vascularization, and the proliferation of glandular cells and fibroblasts; this might be deeply involved in the recurrence and refractoriness of ECRS. The results of our study indicate that TRPV3 is expressed in the nasal polyps of ECRS but the function of TRPV3 in the nasal polyps remains unknown. Further investigation is required to evaluate the function of TRPV3 in the nasal polyps of ECRS. A TRPV3 antagonist has been created\textsuperscript{37} and moved into Phase-II clinical trials for the treatment of neuropathic pain, and additional studies on TRPV3 agonists and antagonists might uncover new therapeutic opportunities for ECRS.

We compared our RNA-seq data with the microarray measurements performed on the same samples. The numbers of transcripts detected by microarray and RNA-seq were 34,692 and 19,932.
respectively. Among them, the number of transcripts identified by both methods was 16,862. The RNA-seq and microarray results were strongly correlated for gene-expression levels obtained with log-transformed FC values ($R = 0.75, p < 0.001$) (Supplementary Fig. 1). In the case of TRPV3, a significant difference in expression was not detected using microarray analysis, but was confirmed using RNA-seq. Furthermore, real-time PCR and immunofluorescence staining showed high expression of TRPV3 in both nasal polyps and peripheral eosinophils. On the other hand, Saito et al. performed the microarray analysis of peripheral eosinophils, which could not detect high expression of TRPV3. They used the GeneChip® Human Genome U133A probe array (Affymetrix, Santa Clara, CA, USA), whereas we used the HumanHT-12 v4 Expression BeadChip Kit (Illumina). Neither of the two arrays could detect high expression of TRPV3. This discrepancy between microarray and RNA-seq may be due to an inappropriate probe hybridized with TRPV3 in microarray kit. Sensitivity of probe is defined by how strongly a probe binds to its target sequence. It affects the strength of the signal read from the microarray.

The rate of concordance between microarray data and RNA-seq data has been investigated in several preceding studies. For instance, Sultan et al. measured gene expression difference between two human cell lines (B cells and embryonic kidney cells) and reported that the log-transformed FC values obtained using the two methods significantly correlated ($R = 0.88$). Wang et al. reviewed a comparison of the data from two studies that examined the yeast transcriptome by using microarrays and RNA-seq. Wang et al. found that the correlation was very low ($R = 0.099–0.177$) at low transcript levels in RNA-seq, but comparatively higher ($R = 0.509$) at moderate transcript levels. This might reflect the narrow dynamic range of microarrays than RNA-seq. Fu et al. compared three methods employed for gene expression analysis of human brain samples: use of RNA-seq, microarrays, and mass spectrometry. The correlation coefficient between the microarray data and the RNA-seq data ranged from 0.51 to 0.67, which depend on the type of samples. Moreover, protein abundances quantified using mass spectrometry, which were converted into the equivalent levels of mRNAs, correlated more strongly for the RNA-seq data than for the microarray data. On the other hand, Malone et al. showed that high correlations were noted when directly matching microarray intensity values with RNA-seq read counts, although lower correlations were found when matching FC values. A high concordance between RNA-seq data and microarray data was detected in human T cells and in a rat pain model as well. The different strengths of correlations reported by these studies indicate a lack of integrity when assessing the level to which the two methods apply. Here, we report an extent of correspondence between RNA-seq data and microarray data that agrees with the aforementioned reports. The correlation of log-transformed FC values was high.

**Acknowledgments**

We thank Makiko Imamura and Hiroko Tsuchiya for their excellent assistance. This study was supported by a Grant-in-Aid for Scientific Research (C) (16K11208) and a Grant-in-Aid for Young Scientists (B) (26861360) from the Japan Society for the Promotion of Science, KAKENHI.

This study received the 2015 JSA Best Presentation Award by the Japanese Society of Allergology.

**Appendix A. Supplementary data**

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.alit.2017.04.002.

**Conflict of interest**

The authors have no conflict of interest to declare.

**Authors’ contributions**

TTo and EN conceived and designed the study. TN and YI collected clinical data. TTo managed and analyzed the data. TTo, MS, and TTa interpreted the results. TTo, EN, and SF wrote the manuscript. All authors critically read and approved the manuscript.

**References**


44. Malone JH, Oliver B. Microarrays, deep sequencing and the true measure of the transcriptome. Nat Methods 2011;8:439–47.